A share price of Bolt Biotherapeutics Inc [BOLT] is currently trading at $0.63, down -0.62%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BOLT shares have gain 9.82% over the last week, with a monthly amount drifted -6.55%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bolt Biotherapeutics Inc [NASDAQ: BOLT] stock has seen the most recent analyst activity on January 06, 2022, when Morgan Stanley downgraded its rating to a Equal-Weight. Previously, SVB Leerink started tracking the stock with Outperform rating on March 02, 2021, and set its price target to $36. On March 02, 2021, Stifel initiated with a Buy rating and assigned a price target of $40 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $45 on March 02, 2021. Guggenheim initiated its recommendation with a Buy and recommended $42 as its price target on March 02, 2021.
Bolt Biotherapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.54 and $1.56. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Bolt Biotherapeutics Inc [NASDAQ: BOLT] shares were valued at $0.63 at the most recent close of the market. An investor can expect a potential return of 58.73% based on the average BOLT price forecast.
Analyzing the BOLT fundamentals
Trailing Twelve Months sales for Bolt Biotherapeutics Inc [NASDAQ:BOLT] were 9.78M which represents -54.87% decline. Gross Profit Margin for this corporation currently stands at -0.68% with Operating Profit Margin at -7.76%, Pretax Profit Margin comes in at -6.66%, and Net Profit Margin reading is -6.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.69 and Total Capital is -0.83.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6041 points at the first support level, and at 0.5821 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6440, and for the 2nd resistance point, it is at 0.6619.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Bolt Biotherapeutics Inc [NASDAQ:BOLT] is 3.16. Further, the Quick Ratio stands at 3.16, while the Cash Ratio is 0.52. Considering the valuation of this stock, the price to sales ratio is 2.45, the price to book ratio is 0.33.
Transactions by insiders
Recent insider trading involved Quinn William P., Chief Financial Officer, that happened on Dec 12 ’23 when 7500.0 shares were purchased. Chief Financial Officer, Quinn William P. completed a deal on Dec 06 ’23 to buy 2500.0 shares. Meanwhile, Director ENGLEMAN EDGAR sold 0.12 million shares on Nov 30 ’23.
